SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-020776
Filing Date
2024-03-07
Accepted
2024-03-07 16:05:21
Documents
16
Period of Report
2024-03-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0201328-8k_elevailabs.htm   iXBRL 8-K 35977
2 DIRECTOR OFFER LETTER TO MR. GEORGE KOVALYOV ea0201328ex10-1_elevailabs.htm EX-10.1 33185
3 GRAPHIC ex10-1_001.jpg GRAPHIC 11507
  Complete submission text file 0001213900-24-020776.txt   272899

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE elab-20240301.xsd EX-101.SCH 3030
5 XBRL LABEL FILE elab-20240301_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE elab-20240301_pre.xml EX-101.PRE 22369
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0201328-8k_elevailabs_htm.xml XML 3723
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

IRS No.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 24730035
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)